Global Uveitis Treatment Market

Uveitis is the term that describes a group of inflammatory diseases that affect the eye and produces swelling. Uveitis can reduce sight and may cause vision loss. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn’s disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.

The main driver for the growth of uveitis market is the rise in prevalence and complications related to uveitis. In addition, increase in prevalence rates, market players betting heavily on research and development to develop new drugs, an introduction of biologics into the market, fast approval of the drugs are fueling the market growth of uveitis treatment market. According to the Ocular Immunology and Uveitis Foundation, worldwide 2,359,242 people are estimated to have the disorder. Even there are significant advances in research and therapeutics, a prevalence of blindness secondary to uveitis has not been reduced in the past thirty years. However, few factors are restraining the growth of the market such as side effects of the drugs, eye irritation and lack of awareness about eye disorders in undeveloped regions, lack of sufficient healthcare infrastructure is hindering the uveitis treatment system market.

Uveitis treatment market segmented based on drug class, disease type, by cause and distribution channel

Uveitis Treatment Market

Based on drug class, uveitis drugs market is segmented into

• Corticosteroids
• Immunosuppressant
• Monoclonal antibodies
• Antibiotics
• Antivirals
• Antifungal
• Analgesics

Based on disease type, uveitis drugs market is segmented into

• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

Based on cause, uveitis drugs market is segmented into

• Infectious Uveitis
• Non-Infectious Uveitis

Based on distribution channel, uveitis drugs market is segmented into

• Hospital Pharmacies
• Retail Pharmacies
• Others

Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies. Considering the aforementioned factors global uveitis treatment market is expected to grow at the significant rate during the forecast period.

Geographically global uveitis treatment market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading in uveitis treatment market due to various factors such as early approval of drugs compared to other regions, increased R&D investments by market players, and high prevalence of the uveitis is contributing growth of the market. In Europe region due to increased prevalence of diseases such as HIV, multiple sclerosis that are underlying causes of uveitis conditions. Japan, China, and India are expected to play important role in the revenue growth of the Asia-Pacific uveitis treatment market. China and India market growth is due to rapidly developing healthcare infrastructure, increased research and development expenditure and growing awareness about the eye-related diseases. However, manufacturing of eye preparations required aseptic conditions and the manufacturing plant should be GMP certified. Hence the cost related to these preparations is very high that has the direct implication on a cost of the drugs.

Some of the players in global uveitis treatment market include AbbVie Inc. (U.S.), Eyegate Pharmaceuticals Inc. (US), Valeant Pharmaceuticals (Bausch + Lomb) (Canada), Novartis AG (Switzerland), Alimera Sciences Inc. (U.S.) and Santen Pharmaceutical Co. Ltd (Japan) to name a few.

• In June 2016, U.S. Food and Drug Administration approved AbbVie’s HUMIRA for the treatment of non-infectious intermediate, posterior and panuveitis

Report Outline:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Table of Content

1.Executive summary

2. Global Uveitis Treatment Market Introduction

 2.1. Global Uveitis Treatment Market – Taxonomy

 2.2. Global Uveitis Treatment Market –Definitions

 2.2.1. Drug Class Type

 2.2.2. Disease Type

 2.2.3. Cause

 2.2.4. Distribution Channel

3. Global Uveitis Drugs Market Dynamics

 3.1. Drivers

 3.2. Restraints

 3.3. Opportunities/Unmet Needs of the Market

 3.4. Trends

 3.5. Global Uveitis Treatment Market Dynamics – Factors Impact Analysis

 3.6. Global Uveitis Treatment Market – Regulations

 3.6.1. U.S

 3.6.2. Europe

 3.6.3. Japan

 3.6.4. China

 3.7. Global Uveitis Treatment Market – Product Innovations

4. Global Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

 4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 4.3. Market Oppurtunity Analysis

5. Global Uveitis Treatment Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024

 5.1. Corticosteroids

 5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 5.1.3. Market Opportunity Analysis

 5.2. Immunosuppressant

 5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 5.2.3. Market Opportunity Analysis

 5.3. Monoclonal antibodies

 5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 5.3.3. Market Opportunity Analysis

 5.4. Antibiotics

 5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 5.4.3. Market Opportunity Analysis

 5.5. Antivirals

 5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 5.5.3. Market Opportunity Analysis

 5.6. Antifungal

 5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 5.6.3. Market Opportunity Analysis

 5.7. Analgesics

 5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 5.7.3. Market Opportunity Analysis

6. Global Uveitis Treatment Market Forecast, By Disease Type, 2013 – 2017 and Forecast, 2018 – 2024

 6.1. Anterior Uveitis

 6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 6.1.3. Market Opportunity Analysis

 6.2. Posterior Uveitis

 6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 6.2.3. Market Opportunity Analysis

 6.3. Intermediate Uveitis

 6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 6.3.3. Market Opportunity Analysis

 6.4. Panuveitis

 6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 6.4.3. Market Opportunity Analysis

7. Global Uveitis Drugs Market Forecast, By Cause, 2013 – 2017 and Forecast, 2018 – 2024

 7.1. Infectious Uveitis

 7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 7.1.3. Market Opportunity Analysis

 7.2. Non-Infectious Uveitis

 7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 7.2.3. Market Opportunity Analysis

8. Global Uveitis Treatment Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024

 8.1. Hospital Pharmacies

 8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 8.1.3. Market Opportunity Analysis

 8.2. Retail Pharmacies

 8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 8.2.3. Market Opportunity Analysi

 8.3. Others

 8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 8.3.3. Market Opportunity Analysis

9. Global Uveitis Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024

 9.1. North America

 9.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 9.1.3. Market Opportunity Analysis

 9.2. Europe

 9.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 9.2.3. Market Opportunity Analysis

 9.3. Asia-Pacific

 9.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 9.3.3. Market Opportunity Analysis

 9.4. Latin America

 9.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 9.4.3. Market Opportunity Analysis

 9.5. Middle East and Africa

 9.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

 9.5.3. Market Opportunity Analysis

 9.6. Global Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class Type, By  Disease Type, Cause, Distribution Channel, and Region, 2018 – 2024

10. North America Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

 10.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

 10.1.1.1. Corticosteroids

 10.1.1.2. Immunosuppressant

 10.1.1.3. Monoclonal antibodies

 10.1.1.4. Antibiotics

 10.1.1.5. Antivirals

 10.1.1.6. Antifungal

 10.1.1.7. Analgesics

 10.1.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 10.1.2.1. Anterior Uveitis

 10.1.2.2. Posterior Uveitis

 10.1.2.3. Intermediate Uveitis

 10.1.2.4. Panuveitis

 10.1.3. Cause Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 10.1.3.1. Infectious Uveitis

 10.1.3.2. Non Infectious Uveitis

 10.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 10.1.4.1. Hospital Pharmacies

 10.1.4.2. Retail Pharmacies

 10.1.4.3. Others

 10.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

 10.1.5.1. U.S.

 10.1.5.2. Canada

 10.1.6. North America Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2018 – 2024

 10.1.7. North America Uveitis Treatment Market Dynamics – Trends

11. Europe Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

 11.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

 11.1.1.1. Corticosteroids

 11.1.1.2. Immunosuppressant

 11.1.1.3. Monoclonal antibodies

 11.1.1.4. Antibiotics

 11.1.1.5. Antivirals

 11.1.1.6. Antifungal

 11.1.1.7. Analgesics

 11.1.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 11.1.2.1. Anterior Uveitis

 11.1.2.2. Posterior Uveitis

 11.1.2.3. Intermediate Uveitis

 11.1.2.4. Panuveitis

 11.1.3. Cause Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 11.1.3.1. Infectious Uveitis

 11.1.3.2. Non Infectious Uveitis

 11.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 11.1.4.1. Hospital Pharmacies

 11.1.4.2. Retail Pharmacies

 11.1.4.3. Others

 11.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 11.1.5.1. Germany

 11.1.5.2. UK

 11.1.5.3. France

 11.1.5.4. Spain

 11.1.5.5. Italy

 11.1.5.6. Russia

 11.1.5.7. Poland

 11.1.5.8. Rest of Europe

 11.1.6. Europe Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2018 – 2024

 11.1.7. Europe Uveitis Treatment Market Dynamics – Trends

12. Asia-Pacific Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

 12.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

 12.1.1.1. Corticosteroids

 12.1.1.2. Immunosuppressant

 12.1.1.3. Monoclonal antibodies

 12.1.1.4. Antibiotics

 12.1.1.5. Antivirals

 12.1.1.6. Antifungal

 12.1.1.7. Analgesics

 12.1.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 12.1.2.1. Anterior Uveitis

 12.1.2.2. Posterior Uveitis

 12.1.2.3. Intermediate Uveitis

 12.1.2.4. Panuveitis

 12.1.3. Cause Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 12.1.3.1. Infectious Uveitis

 12.1.3.2. Non Infectious Uveitis

 12.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 12.1.4.1. Hospital Pharmacies

 12.1.4.2. Retail Pharmacies

 12.1.4.3. Others

 12.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

 12.1.5.1. Japan

 12.1.5.2. China

 12.1.5.3. India

 12.1.5.4. ASEAN

 12.1.5.5. Australia & New Zealand

 12.1.5.6. Rest of Asia-Pacific

 12.1.6. Asia-Pacific Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2018 – 2024

 12.1.7. Europe Uveitis Treatment Market Dynamics – Trends

13. Latin America Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

 13.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

 13.1.1.1. Corticosteroids

 13.1.1.2. Immunosuppressant

 13.1.1.3. Monoclonal antibodies

 13.1.1.4. Antibiotics

 13.1.1.5. Antivirals

 13.1.1.6. Antifungal

 13.1.1.7. Analgesics

 13.1.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 13.1.2.1. Anterior Uveitis

 13.1.2.2. Posterior Uveitis

 13.1.2.3. Intermediate Uveitis

 13.1.2.4. Panuveitis

 13.1.3. Cause Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 13.1.3.1. Infectious Uveitis

 13.1.3.2. Non Infectious Uveitis

 13.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 13.1.4.1. Hospital Pharmacies

 13.1.4.2. Retail Pharmacies

 13.1.4.3. Others

 13.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 13.1.5.1. Brazil

 13.1.5.2. Mexico

 13.1.5.3. Argentina

 13.1.5.4. Venezuela

 13.1.5.5. Rest of Latin America

 13.1.6. Latin America Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2018 – 2024

 13.1.7. Latin America Uveitis Treatment Market Dynamics – Trends

14. Middle East and Africa Uveitis Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

 14.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

 14.1.1.1. Corticosteroids

 14.1.1.2. Immunosuppressant

 14.1.1.3. Monoclonal antibodies

 14.1.1.4. Antibiotics

 14.1.1.5. Antivirals

 14.1.1.6. Antifungal

 14.1.1.7. Analgesics

 14.1.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 14.1.2.1. Anterior Uveitis

 14.1.2.2. Posterior Uveitis

 14.1.2.3. Intermediate Uveitis

 14.1.2.4. Panuveitis

 14.1.3. Cause Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 14.1.3.1. Infectious Uveitis

 14.1.3.2. Non Infectious Uveitis

 14.1.4. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

 14.1.4.1. Hospital Pharmacies

 14.1.4.2. Retail Pharmacies

 14.1.4.3. Others

 14.1.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

 14.1.5.1. Gulf Cooperation Council (GCC) Countries

 14.1.5.2. Israel

 14.1.5.3. South Africa

 14.1.5.4. Rest of MEA

 14.1.6. MEA Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2018 – 2024

 14.1.7. MEA Uveitis Treatment Market Dynamics – Trends

15. Competition Landscape

 15.1. Strategic Dashboard of Top Market Players

 15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

 15.2.1. AbbVie Inc. (U.S.)

 15.2.2. Eyegate Pharmaceuticals Inc. (U.S.)

 15.2.3. Valeant Pharmaceuticals (Bausch + Lomb) (Canada)

 15.2.4. Novartis AG (Switzerland)

 15.2.5. Alimera Sciences Inc. (U.S.)

 15.2.6. Santen Pharmaceutical Co. Ltd (Japan)

16. Research Methodology
17. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

ASK ANALYST

OR

Request Customisation